En Es
Categories

Industry News

Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

18 Jan 2018
Siemens Healthineers Strategy 2025 to Focus on AI
Siemens Healthineers has laid out its strategy to bolster its market leadership by 2025 and beyond, aimed at accelerating profitable growth and delivering return. The company has stated that it is well prepared to take advantage of the paradigm shift and structural growth opportunities in healthcare.
Read More
16 Jan 2018
GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform
GE Healthcare and Roche have entered into a strategic, long-term partnership to jointly develop and co-market digital clinical decision support solutions. Initially, the partnership will focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Read More
16 Jan 2018
Global Ultrasound Market to Reach USD 6.86 Billion by 2021
The global ultrasound market is expected to grow at a CAGR of 5.2% during 2016 to 2021 to reach a value of USD 6.86 billion by 2021, driven by a growing patient population base for chronic and lifestyle-related disorders, technological advancements, and increasing demand for minimally invasive diagnostic and therapeutic techniques.
Read More
16 Jan 2018
Top Challenges for Medical Device Manufacturers in Emerging Markets
The emerging markets are expected to provide significant growth opportunities for manufacturers of medical devices due to their increasing importance in modern healthcare. In spite of the positive outlook for the emerging medical devices markets, manufacturers will need to overcome some challenges related to product quality, regulatory compliance, and data security, according to Infiniti Research, a full service business intelligence and market research firm.
Read More
16 Jan 2018
Smart Pills Market Worth USD 3 Billion by 2025
The global smart pills market was valued at USD 779.4 million in 2016 and is expected to grow at a CAGR of 15.5% during the forecast period (2017-2025) to reach USD 3.0 billion by 2025, driven by the increased prevalence of colorectal cancer and gastrointestinal disorders, geographical expansion by the major players, rising cancer screening awareness programs and faster FDA approvals.
Read More
09 Jan 2018
Global POC Infectious Disease Market to Reach USD 1.9 Billion by 2025
The global point-of-care (POC) infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025, as the emerging trend of patient-centric services and increase in complicated infectious disorders drives an upsurge in the demand for portable and accurate detection devices.
Read More
09 Jan 2018
Global Surgical Table Market Driven by Increase in Healthcare Expenditures
The global surgical table market is expected to grow at a CAGR of 2.9% from 2018 to 2023, driven by rising healthcare expenditures, increasing number of hospitals, adoption of hybrid operating rooms, and improved healthcare facilities. These are the latest findings of Research and Markets, a global market research company.
Read More
09 Jan 2018
Toshiba Medical Systems Changes Name to Canon Medical Systems
The official corporate name of Toshiba Medical Systems Corporation has been changed to Canon Medical Systems Corporation. The name change follows the completion of procedures for obtaining regulatory approval for integration with the Canon Group after the company officially became a subsidiary of Canon Inc. in December 2016. Similarly, Toshiba America Medical Systems, now a Canon group company, has been officially named as Canon Medical Systems USA, Inc.
Read More
02 Jan 2018
Fewer Pathologists and More Cancer Patients Drive Pathology Market
The global digital pathology market was worth USD 381.8 million in 2016 and is projected to grow at a CAGR of 13.2% to reach USD 708.9 million by 2021, driven by the increased adoption of digital pathology solutions worldwide due to shortage of pathologists and rise in new cancer cases. Additionally, new business models and increased FDA approvals of Whole Slide Image (WSI) scanners for primary diagnostics are expected to provide a boost to the digital pathology market.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions